Venus Concept Inc. (NASDAQ:VERO) Short Interest Down 35.0% in December

Venus Concept Inc. (NASDAQ:VERO) was the target of a large decrease in short interest in December. As of December 15th, there was short interest totaling 93,597 shares, a decrease of 35.0% from the November 30th total of 144,013 shares. Approximately 9.1% of the shares of the stock are short sold. Based on an average daily volume of 645,091 shares, the short-interest ratio is currently 0.1 days. Based on an average daily volume of 645,091 shares, the short-interest ratio is currently 0.1 days. Approximately 9.1% of the shares of the stock are short sold.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Venus Concept in a research report on Wednesday, October 8th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company currently has an average rating of “Sell”.

Venus Concept Price Performance

Venus Concept stock opened at $1.66 on Tuesday. The stock has a market cap of $2.36 million, a price-to-earnings ratio of -0.03 and a beta of -0.11. The company has a quick ratio of 0.59, a current ratio of 0.90 and a debt-to-equity ratio of 1.59. The business has a 50-day simple moving average of $1.93 and a 200 day simple moving average of $2.25. Venus Concept has a 52 week low of $1.63 and a 52 week high of $14.50.

Venus Concept (NASDAQ:VERO) last released its quarterly earnings results on Thursday, November 13th. The company reported ($12.14) earnings per share for the quarter, missing the consensus estimate of ($3.61) by ($8.53). Venus Concept had a negative net margin of 92.76% and a negative return on equity of 1,904.25%. The business had revenue of $13.78 million during the quarter, compared to analysts’ expectations of $14.48 million.

Venus Concept Company Profile

Venus Concept Ltd. (NASDAQ: VERO) is a Canada-based medical aesthetic device company that designs, develops and commercializes minimally and noninvasive solutions for face and body rejuvenation. The company’s core product portfolio leverages proprietary technologies such as multi-polar radio frequency, pulsed electromagnetic fields and intense pulsed light to offer treatments for skin tightening, body contouring, wrinkle reduction and vascular lesion removal.

Among its flagship offerings are the Venus Legacy platform, which combines radio frequency and electromagnetic pulses for cellulite reduction and circumferential reduction, and the Venus Versa system, a multi-application device for facial revitalization, acne treatment, hair removal and photorejuvenation.